AIMS/HYPOTHESIS: The aim of this prospective study was to determine whether circulating intercellular adhesion molecule (ICAM) 1, as a potential surrogate of 'endothelial activation', is more strongly associated with risk of vascular events than with incident diabetes. METHODS: We related baseline ICAM-1 levels to vascular events (866 CHD and stroke events in 5,685 participants) and incident diabetes (292 in 4,945 without baseline diabetes) in the elderly over 3.2 years of follow-up. RESULTS: ICAM-1 levels correlated positively with triacylglycerol but negatively with LDL- and HDL-cholesterol. ICAM-1 levels were higher in those who developed diabetes (388.6 +/- 1.42 vs 369.4 +/- 1.39 ng/ml [mean+/-SD], p = 0.011) and remained independently associated with new-onset diabetes (HR 1.84, 95% CI 1.26-2.69, p = 0.0015 per unit increase in log[ICAM-1] after adjusting for classical risk factors and C-reactive protein). By contrast, ICAM-1 levels were not significantly (p = 0.40) elevated in those who had an incident vascular event compared with those who remained event-free, and corresponding adjusted risk associations were null (HR 0.98, 95% CI 0.80-1.22, p = 0.89) in analyses adjusted for other risk factors. CONCLUSIONS/ INTERPRETATION: We show that elevated ICAM-1 levels are associated with risk of incident diabetes in the elderly at risk, despite no association with incident cardiovascular disease risk. We suggest that perturbations in circulating ICAM-1 levels are aligned more towards diabetes risk.
AIMS/HYPOTHESIS: The aim of this prospective study was to determine whether circulating intercellular adhesion molecule (ICAM) 1, as a potential surrogate of 'endothelial activation', is more strongly associated with risk of vascular events than with incident diabetes. METHODS: We related baseline ICAM-1 levels to vascular events (866 CHD and stroke events in 5,685 participants) and incident diabetes (292 in 4,945 without baseline diabetes) in the elderly over 3.2 years of follow-up. RESULTS:ICAM-1 levels correlated positively with triacylglycerol but negatively with LDL- and HDL-cholesterol. ICAM-1 levels were higher in those who developed diabetes (388.6 +/- 1.42 vs 369.4 +/- 1.39 ng/ml [mean+/-SD], p = 0.011) and remained independently associated with new-onset diabetes (HR 1.84, 95% CI 1.26-2.69, p = 0.0015 per unit increase in log[ICAM-1] after adjusting for classical risk factors and C-reactive protein). By contrast, ICAM-1 levels were not significantly (p = 0.40) elevated in those who had an incident vascular event compared with those who remained event-free, and corresponding adjusted risk associations were null (HR 0.98, 95% CI 0.80-1.22, p = 0.89) in analyses adjusted for other risk factors. CONCLUSIONS/ INTERPRETATION: We show that elevated ICAM-1 levels are associated with risk of incident diabetes in the elderly at risk, despite no association with incident cardiovascular disease risk. We suggest that perturbations in circulating ICAM-1 levels are aligned more towards diabetes risk.
Authors: S J Hwang; C M Ballantyne; A R Sharrett; L C Smith; C E Davis; A M Gotto; E Boerwinkle Journal: Circulation Date: 1997-12-16 Impact factor: 29.690
Authors: Yiqing Song; JoAnn E Manson; Lesley Tinker; Nader Rifai; Nancy R Cook; Frank B Hu; Gokhan S Hotamisligil; Paul M Ridker; Beatriz L Rodriguez; Karen L Margolis; Albert Oberman; Simin Liu Journal: Diabetes Date: 2007-03-27 Impact factor: 9.461
Authors: I Malik; J Danesh; P Whincup; V Bhatia; O Papacosta; M Walker; L Lennon; A Thomson; D Haskard Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Naveed Sattar; Alex McConnachie; A Gerald Shaper; Gerard J Blauw; Brendan M Buckley; Anton J de Craen; Ian Ford; Nita G Forouhi; Dilys J Freeman; J Wouter Jukema; Lucy Lennon; Peter W Macfarlane; Michael B Murphy; Chris J Packard; David J Stott; Rudi G Westendorp; Peter H Whincup; James Shepherd; S Goya Wannamethee Journal: Lancet Date: 2008-05-22 Impact factor: 79.321
Authors: Dennis M J Muris; Alfons J H M Houben; Miranda T Schram; Coen D A Stehouwer Journal: Rev Endocr Metab Disord Date: 2013-03 Impact factor: 6.514
Authors: J S Pankow; P A Decker; C Berardi; N Q Hanson; M Sale; W Tang; A M Kanaya; N B Larson; M Y Tsai; C L Wassel; S J Bielinski Journal: Diabet Med Date: 2016-03-25 Impact factor: 4.359
Authors: Daniel A Duprez; Nkete I Forbang; Matthew A Allison; Carmen A Peralta; Steven Shea; David R Jacobs Journal: Cardiovasc Diabetol Date: 2019-05-17 Impact factor: 9.951
Authors: Ashley M Miller; David Purves; Alex McConnachie; Darren L Asquith; G David Batty; Harry Burns; Jonathan Cavanagh; Ian Ford; Jennifer S McLean; Chris J Packard; Paul G Shiels; Helen Turner; Yoga N Velupillai; Kevin A Deans; Paul Welsh; Iain B McInnes; Naveed Sattar Journal: PLoS One Date: 2012-10-24 Impact factor: 3.240